Lyell Immunopharma's market cap is currently ―. The company's EPS TTM is $-0.935; its P/E ratio is -2.34; Lyell Immunopharma is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-0.21. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 13.00K	$ 25.00K	$ 27.00K	$ 65.00K	$ 48.39M
Gross Profit	$ 13.00K	$ 25.00K	$ 27.00K	$ 65.00K	$ 48.39M
EBIT	$ -52.93M	$ -50.85M	$ -63.89M	$ -71.46M	$ -11.85M
EBITDA	$ -51.26M	$ -48.04M	$ -60.90M	$ -68.28M	$ -8.02M
Net Income Common Stockholders	$ -52.93M	$ -50.85M	$ -63.89M	$ -66.96M	$ -8.40M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 546.22M	$ 575.43M	$ 595.75M	$ 612.77M	$ 640.15M
Total Assets	$ 750.03M	$ 794.99M	$ 835.35M	$ 880.45M	$ 937.54M
Total Debt	$ 56.89M	$ 58.58M	$ 60.22M	$ 61.83M	$ 63.17M
Net Debt	$ -489.33M	$ -516.86M	$ -535.53M	$ -550.94M	$ -576.98M
Total Liabilities	$ 95.08M	$ 97.42M	$ 98.50M	$ 96.62M	$ 937.56M
Stockholders Equity	$ 654.95M	$ 697.57M	$ 736.86M	$ 783.83M	$ 833.25M
Cash Flow	-
Free Cash Flow	$ -40.66M	$ -37.88M	$ -40.09M	$ 280.00K	-
Operating Cash Flow	$ -40.63M	$ -37.69M	$ -39.16M	$ 280.00K	-
Investing Cash Flow	$ -100.69M	$ 99.67M	$ 152.91M	$ 32.15M	-
Financing Cash Flow	$ 759.00K	$ -143.00K	$ 1.20M	$ -69.00K	-

Currency in USD

Lyell Immunopharma Earnings and Revenue History

Income Statement >

Lyell Immunopharma Debt to Assets

Balance Sheet >

Lyell Immunopharma Cash Flow

Cash Flow >

Lyell Immunopharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing